Pharma Missing Out From Market Access Challenges In China: EU Group
Politicized Environment 'Alarming'
Slower approvals for foreign drugs, a volume-based procurement scheme and localization requirements caused nearly 80% of respondent European pharma firms to miss out on opportunities in China, where they also continue to decouple from headquarters in a “in China-for-China” strategy, a survey from a prominent EU business group shows.
You may also be interested in...
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.